[144] Design Therapeutics, Inc. SEC Filing

Rhea-AI Filing Summary

Design Therapeutics reported a Form 144 notice proposing the sale of 217,627 common shares, with an aggregate market value of $1,083,783.00, scheduled approximately for 08/13/2025 on NASDAQ through broker BTIG, LLC. The filing shows the shares were originally acquired on 01/25/2021 in a private market transaction from Design Therapeutics, with 1,984,733 shares acquired and paid in cash on that date. The filer reports no securities sold in the past three months and affirms they are unaware of any undisclosed material adverse information about the issuer.

Insights

Securities Analyst

TL;DR: A registered holder plans to sell a modest block equal to ~0.38% of outstanding shares, disclosed via Form 144 for transparency.

The Form 144 notifies the market of a proposed sale of 217,627 shares valued at $1,083,783 on 08/13/2025 through BTIG, LLC. Against the reported 56,948,126 shares outstanding, the proposed sale represents approximately 0.38% of the share count. The filer previously acquired 1,984,733 shares on 01/25/2021, so the proposed sale is about 10.96% of that holding. This disclosure is routine and provides market transparency about potential share supply.

Corporate Governance Expert

TL;DR: The filing is a routine insider disclosure that affirms no undisclosed material adverse information and records no recent sales.

The notice includes a signed representation that the filer does not possess material nonpublic information about the issuer. The form also states there were no securities sold in the past three months by the selling person. The sale will be executed via a named broker on the national exchange, aligning with standard compliance and reporting procedures under Rule 144.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
COMMON	BTIG, LLC 350 Bush Street 9th Floor San Francisco CA 94104	217627	1083783.00	56948126	08/13/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
COMMON	01/25/2021	Private Market	Acquired from Design Therapeutics			1984733	01/25/2021	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the Design Therapeutics (DSGN) Form 144 disclose?

The notice discloses a proposed sale of 217,627 common shares valued at $1,083,783.00, to be executed approximately on 08/13/2025 on NASDAQ through BTIG, LLC.

How many shares does the filer originally hold and when were they acquired?

The filer acquired 1,984,733 shares on 01/25/2021 in a private market transaction from Design Therapeutics, paid in cash on that date.

Has the filer sold any securities of the issuer in the past three months?

The Form 144 states "Nothing to Report" for securities sold during the past three months, indicating no reported sales in that period.

Who is the broker and on which exchange will the shares be sold?

The broker named in the filing is BTIG, LLC, 350 Bush Street 9th Floor San Francisco CA 94104, and the sale is listed for execution on NASDAQ.

Does the filing include any representation about material nonpublic information?

Yes. By signing, the person for whose account the securities are sold represents they do not know any material adverse information about the issuer that has not been publicly disclosed.